Based on the key indicators related to Tango Therapeutics' liquidity, profitability, solvency, and operating efficiency, Tango Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At this time, Tango Therapeutics' Short and Long Term Debt Total is fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 301.2 M in 2025, whereas Total Assets are likely to drop slightly above 352.5 M in 2025. Key indicators impacting Tango Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Tango Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Tango Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Tango Therapeutics.
Please note, the imprecision that can be found in Tango Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tango Therapeutics. Check Tango Therapeutics' Beneish M Score to see the likelihood of Tango Therapeutics' management manipulating its earnings.
Tango Therapeutics Stock Summary
Tango Therapeutics competes with Third Harmonic, Cullinan Oncology, Edgewise Therapeutics, Rallybio Corp, and Monte Rosa. Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts. Tango Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 103 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Cash flow analysis captures how much money flows into and out of Tango Therapeutics. It measures of how well Tango is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Tango Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Tango had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Tango Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Tango Therapeutics's current stock value. Our valuation model uses many indicators to compare Tango Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tango Therapeutics competition to find correlations between indicators driving Tango Therapeutics's intrinsic value. More Info.
Tango Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Tango Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tango Therapeutics' earnings, one of the primary drivers of an investment's value.
Tango Therapeutics Systematic Risk
Tango Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tango Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Tango Therapeutics correlated with the market. If Beta is less than 0 Tango Therapeutics generally moves in the opposite direction as compared to the market. If Tango Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tango Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tango Therapeutics is generally in the same direction as the market. If Beta > 1 Tango Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Tango Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tango Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Tango Therapeutics growth as a starting point in their analysis.
Tango Therapeutics January 19, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tango Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tango Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tango Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Tango Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tango Therapeutics's daily price indicators and compare them against related drivers.
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.